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Abstract
Cryopreservation was recommended to ensure continuity of unrelated donor (UD) hematopoietic stem cell transplantation
(HSCT) during COVID-19 pandemic. However, its impact on clinical outcomes and feasibility was not well known. We
compared 32 patients who underwent UD HSCT using cryopreserved peripheral blood stem cells (PBSC) during the
COVID-19 pandemic with 32 patients who underwent UD HSCT using fresh PBSC in the previous period. Median
neutrophil engraftment was 17.5 and 17.0 days with cryopreserved and fresh grafts, respectively. Non-significant delays
were found in platelet recovery days (25.5 versus 19.0; P= 0.192) and full donor chimerism days (35.0 and 31.5; P= 0.872)
using cryopreserved PBSC. The rate of acute graft-versus-host disease at 100 days was 41% (95% CI [21–55%]) in
cryopreserved group versus 31% (95% CI [13–46%]) in fresh group (P= 0.380). One-hundred days progression-relapse free
survival and overall survival did not differ significantly. During COVID-19 pandemic, six frozen UD donations were not
transfused and logistical and clinical issues regarding cryopreservation procedure, packaging, and transporting appeared. In
summary, UD HSCT with cryopreserved PBSC was safe during this challenging time. More efforts are needed to ensure that
all frozen grafts are transplanted and cryopreservation requirements are harmonized.
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Unrelated donor (UD) hematopoietic stem cells (HSC) are
usually freshly transported away from transplant centers
(TCs) by door-to-door courier services shortly after col-
lection. This practice usually allows grafts to be transfused
without the need for a cryopreservation step [1], and is
enabled by the adequate provision of donor products
through the national registries, under the support of the
World Marrow Donor Association.
The emergence of COVID-19 caused by SARS-CoV-2
and the subsequent evolution to a global pandemic sig-
nificantly disrupted graft transportation within and between
countries. Suddenly, transit restrictions for people and
goods made it difficult to guarantee the timely delivery of
fresh UD HSC, which is a requirement for successful
transplantation [1]. Moreover, the concern that the donor
could be at risk of community-acquired infection once the
patients had started the conditioning procedure led profes-
sional societies to recommend immediately the cryopre-
servation of grafts [2–4]. However, evidence about the
feasibility of cryopreservation prior to UD HSC was scarce,
since most of the literature has approached this topic within
the context of match-related donors (MRD) [5–9], where
logistics and time from collection to cryopreservation are
perfectly controlled, and the few studies available have
yielded controversial results [5, 10, 11].
The aim of the present study was to retrospectively
investigate the clinical outcomes, namely myeloid engraft-
ment, full donor chimerism, acute graft-versus-host disease
(GVHD), preemptive therapy on cytomegalovirus (CMV)
disease, progression-relapse-free survival (PFS), and overall
survival (OS), of patients who underwent UD hematopoietic
stem cell transplantation (HSCT) with cryopreserved per-
ipheral blood stem cells (PBSC) during COVID-19 pan-
demic, and compare them with those of patients who had
undergone UD HSCT with fresh PBSC in the immediately
previous period, as well as to identify frozen grafts not used,
and logistical and clinical issues related to the cryopre-
servation of UD HSC during the COVID-19 pandemic.
Materials and methods
Donors and patients
All donors and recipients provided written informed consent
prior to collection and transplantation. The Vall d’Hebron
University Hospital’s Ethics Committee reviewed and
approved the study [CEIC code PR(AG)355/2020]. Elig-
ibility criteria for patients were: (i) first allo-HSCT, (ii) non-
manipulated UD PBSC as graft source, (iii) no presence of
donor-specific anti-human leukocyte antigen (HLA)
antibodies (DSA), and (iv) partial or complete disease
remission status at the time of the transplantation procedure.
All consecutive patients meeting these criteria who under-
went transplantation from June 2019 to October 2020 with
grafts provided by Banc de Sang i Teixits’ (BST) Cell
Therapy Service were retrospectively included in the study
and stratified in two groups regarding the use of cryopre-
served grafts during the COVID-19 pandemic or fresh grafts
in the previous time. Recipients were longitudinally fol-
lowed until death or by day +100 after HSCT, whatever
occurred first.
All patients were tested for SARS-CoV-2 by PCR before
starting the conditioning procedure regardless of whether or
not they presented with any symptoms. Donors were tested
for SARS-CoV-2 prior to collection. Regarding UD HSC
from countries where COVID-19 screening was not man-
datory, a cryoquarantine of 14 days was required for these
products by the Spanish Health Authority [12].
Cryopreservation procedure
For cryopreservation, leukapheresis material was con-
centrated prior to cryoprotection at <300 × 106 TNC/mL.
The cryopreservation solution consisted of 10% dimethyl
sulfoxide (DMSO), 4% human serum albumin, and 5%
citrate dextrose solution A in Plasma-Lyte. A controlled-
rate/programmable freezer CM2010 (Carburos Medica,
Barcelona, Spain) was used at <−5 °C/min, and storage was
performed at <−150 °C in vapor phase of liquid nitrogen.
Three 0.5 mL aliquots of the cell preparation were frozen
together with the bag and were used to perform the
appropriate quality controls: blood cell count; flow cyto-
metry assessment of CD45, CD34, and CD3 expression
according to the ISHAGE protocol single-platform multi-
gating strategy adjusting for forward side scatter, straight
side scatter, CD45 and CD34 [13], and of viability using 7-
aminoactinomycin D (7-AAD); colony-forming unit (CFU)
assay using Methocult 4434 from Stem Cell Technologies
(Vancouver, Canada) supplemented with Iscove’s Modified
Dulbecco’s Medium from BIOWEST (Nuaillé, France).
Definitions
Neutrophil recovery was considered to occur on the first of
3 consecutive days with an absolute neutrophil count >500/
µL after the post-transplantation nadir. Platelet recovery
date was the first of 3 consecutive days with a platelet count
>20,000/µL, in the absence of platelet transfusion for 7
consecutive days. Full donor chimerism date was defined as
the first day with complete donor chimerism (100% donor)
in total cells and/or peripheral cell subpopulations (CD15
and CD3), and was analyzed with a panel of 12 poly-
morphic short tandem repeat markers using the MentypeTM
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kit from Biotype (Dresden, Germany). Graft failure (GF)
was defined as having never achieved absolute neutrophil
count >500/µL, autologous recovery, or loss of donor
engraftment. Acute GVHD was defined and graded
according to standard criteria [14, 15]. Preemptive therapy
on CMV disease was considered when initiation of antiviral
therapy for early asymptomatic CMV viremia detected by
surveillance testing was started. PFS was defined as survival
without progression or relapse of primary disease.
Available information about the reasons why some
cryopreserved grafts were not finally used during the
COVID-19 pandemic and until February 1, 2021 was
registered, and serious adverse reactions (SAR) or events
occurring in patients or in the procurement, respectively,
were also recorded [16]. Regarding logistical issues any
incident that happened throughout the process (cryopre-
servation, packaging, and transportation) was documented.
Study endpoints
The primary study endpoint was to compare hematological
recovery (neutrophil and platelet engraftment) and full
donor chimerism between patients who underwent UD
HSCT with cryopreserved, non-manipulated PBSC during
COVID-19 pandemic in Spain (March 13 to November 1,
2020) and those who had undergone the procedure with
fresh non-manipulated PBSC in the immediately previous
period (June 1, 2019 to March 12, 2020). Secondary end-
points included comparisons of acute GVHD, preemptive
therapy on CMV disease, PFS, and OS between both
cohorts. Finally, frozen grafts not transfused and logistical
and clinical issues arising with cryopreserved UD HSC in
the context of the pandemic were also assessed.
Statistical analysis
Two cohorts of UD HSCT were analyzed according to the
use of fresh or cryopreserved products. Patient-, disease-,
transplantation, and graft-related factors were compared
between both groups using a comparison test
(Mann–Whitney U test for quantitative variables and χ2 or
Fisher test for the categorical ones). Median and inter-
quartile range (IQR) or frequency and percentage were used
for quantitative and qualitative variables, respectively. Time
to primary outcomes (neutrophil/platelet engraftment and
100% donor chimerism) and secondary outcomes (acute
GVHD, preemptive therapy on CMV infection, PFS, and
OS) were calculated using survival analyses. Kaplan–Meier
curves and log-rank tests were used to compare both
groups. A cause-specific analysis was performed for each
individual outcome. Deaths without the event were treated
as not-recoverable events. A type-I error of 5% was
considered.
Results
Baseline characteristics of patients and grafts
A total of 47 UD HSC were cryopreserved during the
COVID-19 pandemic. Forty-one patients underwent UD
HSCT. Five and one patients were transplanted with grafts
subjected to major (CD34+ selection) and minor (washing or
red cell depletion) manipulation, respectively, and bone
marrow was used in three patients. All these nine patients
were excluded from the clinical outcomes analysis. Therefore,
32 patients underwent UD HSCT with cryopreserved non-
manipulated PBSC during COVID-19 pandemic and were
compared with 32 patients who had undergone UD HSCT
with fresh non-manipulated PBSC in the immediately pre-
vious period. Results are summarized in Table 1. There were
no statistically significant differences between cohorts in
terms of age, gender, hematologic malignancy, donor/reci-
pient ABO, sex, HLA, or CMV serostatus compatibility.
Conditioning, GVHD prophylaxis and prognosis index were
comparable between two cohorts. Regarding graft character-
istics (Table 1), no differences were observed between both
groups except in the median number of CD34+ cells/kg
(×106) prior to freezing or transfused in fresh, which was
higher in those patients transplanted with cryopreserved grafts
(6.0 versus 5.2; P= 0.016). The quality control in the post-
thawing reference samples of cryopreserved products is
shown in Table 2. After cryopreservation, the median loss
of viable CD34+ cells was 24.2%. The median (IQR) of
CD45+/7-AAD negative cells and CD3+/7-AAD negative
cells were 66.8% (52.8–74.6) and 48.4% (33.7–64.8),
respectively.
Clinical outcomes
Table 3 shows the univariate analysis of neutrophil/platelet
engraftment, full donor chimerism, acute GVHD, preemptive
therapy on CMV disease, PFS, and OS according to UD
HSC. No statistical differences were found in the median
days, the rate of recovery at day +21 and the cumulative
incidence of neutrophil engraftment (Fig. 1A) between both
groups. All patients transplanted with fresh grafts achieved
neutrophil recovery within a median of 17.0 days versus
17.5 days in those transplanted with cryopreserved PBSC. In
the group of patients transplanted with cryopreserved grafts,
one of them reached neutrophil engraftment by day+33 and a
herpes simplex virus 6 infection was detected. Another patient
had GF in spite of an optimal cell dose, viability, and CFU
growth. The median time to platelet recovery was 19.0 days
with fresh grafts and 25.5 days with cryopreserved grafts
(P= 0.192). No statistical differences were observed in the
rate of platelet recovery at days +30 and +100 (Table 2), and
cumulative incidence of platelet engraftment (Fig. 1B). All
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survivors achieved platelet engraftment by 100 days after the
procedure. Regarding full donor chimerism, no statistical
differences were found in the median days, the rate of
achievement at day +30 and +100, and the cumulative
incidence between both cohorts (Table 2 and Fig. 1C). One
and two patients in each group who received fresh and
cryopreserved grafts, respectively, achieved mixed chimerism
by 100 days after transplantation. All three patients had
received RIC conditioning.
The cumulative incidence of acute GVHD (Table 2
and Fig. 2A) observed at day +100 in patients trans-
planted with fresh cells was 31% versus 41% in those
transplanted with cryopreserved cells (P= 0.380). No
statistical differences were observed in incidence of
preemptive therapy on CMV between both groups
(Table 2 and Fig. 2B).
The rates of PFS at day +100 were 81% (95% con-
fidence interval [CI] [69–96]) and 88% (95% CI [77–100])
in fresh and cryopreserved grafts, respectively (P= 0.500)
(Table 2 and Fig. 2C). The corresponding rates of OS at day
+100 were 81% (95% CI [69–96]) and 90% (95% CI
[90–100]) (P= 0.300) (Table 2 and Fig. 2D).
Clinical and logistical issues in cryopreserved grafts
Six of 47 (13%) donated and cryopreserved UD HSC had
not yet been transplanted at February 1, 2021. The main
cause was relapse/progression of underlying disease (three
cases). The others cases corresponded to a patient’s HLA-
typing error that was detected after collection, a patient who
presented with DSA refractory to desensitization treatment
and finally, and one patient who refused HSCT days after
graft cryopreservation. The median (IQR) number of days
that elapsed from collection to transplantation was 21
(21–49). In one case, cryopreserved cells were transfused
175 days after collection.
Only one SAR was documented at transfusion of HPC.
That patient had tachycardia and generalized cutaneous
rash, because of the incompatibility between the external
cryopreserved donor bag and the transfusion set, which
forced healthcare staff to transfuse urgently the cells
manually, which precluded an appropriate transfusion speed
control. An allergic reaction to DMSO was suspected,
which was completely resolved after antihistamine treat-
ment and decreasing transfusion rate.
Table 1 Baseline characteristics of patients according to UD HSC.
Characteristic Cells P value
Fresh (n= 32) Cryopreserved
(n= 32)
Age at transplantation (years), median
(IQR)
50.5 (32.2–61.2) 52 (38–66) 0.333
Sex (female), n (%) 11 (34.4) (28.1) 0.787
Disease, n (%) 0.921
Acute leukemiaa 17 (53.1) 16 (50)
MDS/MPN 6 (18.8) 7 (21.9)
Lymphoma 5 (15.6) 6 (18.8)
Myeloma multiple 4 (12.5) 2 (6.2)
Chronic leukemia 0 (0) 1 (3.1)
ABO D/R incompatibility, n (%) 12 (37.5) 13 (37.5) 1.000
Sex D/R incompatibility, n (%) 12 (37.5) 12 (37.5) 1.000
HLA compatibility, n (%) 0.197
9/10 15 (46.9) 9 (28.1)
10/10 17 (53.1) 23 (71.9)
CMV D/R status, n (%) 0.067
Pos/Pos 20 (62.5) 10 (31.2)
Neg/Pos 8(25) 12 (37.5)
Neg/Neg 2 (6.2) 7 21.9)
Pos/Neg 2 (6.2) 3 (9.4)
Myeloablative conditioning, n (%) 14 (43.8) 14 (43.8) 1.000
GVHD prophylaxis, n (%) 0.577
PTCy 13 (40.6) 17 (53.1)
Cyclosporine 13 (40.6) 11 (34.4)
Tacrolimus 6 (18.8) 4 (12.5)
<90% Karnofsky Index, n (%) 6 (18.8) 4 (12.5) 0.731
Disease Risk Index, n (%) 0.308
Low 4 (12.5) 3 (9.4)
Intermediate 15 (46.9) 21 (65.6)
High 8 (25) 7 (21.9)
Very high 5 (15.6) 1 (3.1)
HCT-CI, n (%) 0.125
0 8 (25) 10 (31.2)
1–2 11 (34.4) 15 (46.9)
>2 13 (40.6) 7 (21.8)
EBMT score, n (%) 0.605
0–2 6 (18.8) 5 (15.6)
3–5 22 (68.8) 20 (62.5)
>5 4 (12.5) 7 (21.9)
Graft characteristics
Number of days of collections, n (%) 1
One 29 (90.6) 30 (93.8)
More than one 3 (9.4) 2 (6.2)
Hours from collection, median (IQR)b 36.2 (29.4–48) 41.9 (29.7–59.4) 0.327
Cellularity, median (IQR)c
TNC × 108/kg 6.4 (5.1–8.7) 6.3 (5.1–7.5) 0.682
Neutrophil × 108/kg 1.1 (0.6–2.4) 1.9 (1.4–2.5) 0.878
CD34+ × 106/kg 5.1 (5–6) 6 (5.6–6) 0.016
CD3+ × 108/kg 1.8 (1.4–2.9) 1.9 (1.4–2.5) 0.878
TNC/mL × 106, median (IQR) 199.5 (173.6–253.6) 210.9 (184.1–273.1) 0.626
% mononuclear cells, median (IQR) 80.6 (73.9–85.3) 83.7 (78.4–90.3) 0.155
Viability, median (IQR)
CD45+/7-AAD negative (%) 98.7 (97.8–99.1) 99 (98.2–99.2) 0.205
CD34+/7-AAD negative (%) 99.2 (99–99.5) 99.3 (99–99.7) 0.538
CD3+/7-AAD negative (%) 98.6 (96.9–99.2) 99 (97.7–99) 0.876
UD HSC unrelated donor hematopoietic stem cell, IQR interquartile
range, MDS/MPN myelodisplastic syndrome/myeloproliferative neo-
plasm, D/R donor/recipient, HLA human leukocyte antigen, GVHD
graft-versus-host disease, PTCy post-transplantation cyclophospha-
mide, HCT-CI hematopoietic cell transplantation-specific comorbidity
index, EBMT European Bone Marrow Transplantation, TNC total
nucleated cell, 7-AAD 7-aminoactinomicine D.
aFour and eight patients with acute lymphoblastic leukemia in fresh
group and cryopreserved group, respectively. Thirteen and eight
patients with acute myeloblastic leukemia in fresh group and
cryopreserved group, respectively.
bTo transfusion (fresh cells) or prior cryopreservation (cryopreserved
cells).
cIn cells to be transfused to fresh group patients (“Fresh” column), or,
prior to cryopreservation, in cells to be transfused to cryopreserved
group patients (“Cryopreserved” column).
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Neither patients nor donors had a SARS-CoV-2
positive test.
The median hours from collection to transfusion or cryo-
preservation was 36.2 with fresh PBSC and 41.9 with frozen
PBSC, respectively (P= 0.327) (Table 1). Such delay was due
to the policy of TC to perform in-house cryopreservation.
Nevertheless, seven UD HSC were cryopreserved at collection
centers because of the unavailability of in-fresh transportation.
In one case, this onsite cryopreservation was unintended and
led to a deviation of procedures that complicated and delayed
quality release of the product for transplantation albeit with no
impact on clinical outcomes. In another case, rapid instructions
to package the cryopreserved product had to be issued to an
external facility and, in a third case, a problem caused by the
incompatibility size between BST’s cell processing laboratory
cassettes and the rack provided by the sender within the dry
shipper had to be overcome.
Discussion
In spite of the fact that reliable randomized, controlled
studies regarding graft cryopreservation impact on clinical
outcomes of patients undergoing UD HSCT were not
available when the COVID-19 pandemic broke out, cryo-
preservation was recommended as a general rule. The aim
of our study was to assess the impact of this recommen-
dation comparing engraftment and clinical outcomes of
patients who underwent UD HSCT with cryopreserved non-
manipulated PBSC during COVID-19 pandemic with those
who had undergone this procedure with fresh non-
manipulated PBSC in the previous period. Also, we
reviewed the unused frozen grafts, and clinical and logis-
tical issues regarding cryopreservation. Our results suggest
that cryopreservation during the COVID-19 pandemic did
not negatively affect neutrophil/platelet engraftment and full
donor chimerism. In order to prevent engraftment delays or
failures, a negative impact of insufficient CD34+ cell dose
on survival outcomes, and cell losses or low viability due to
cryopreservation, the amount of frozen CD34+ cells was
intentionally higher than that transfused in fresh grafts
[17, 18]. Regarding quality control of cryopreserved grafts,
all the UD HSC were fully compliant according to cell
counts, viability and CFUs. CD45+/7-AAD and CD3+/7-
AAD negative cells were lower than 70% due to the impact
of cryopreservation, but this did not influence potency
assays. One GF occurred in the cohort transplanted with
cryopreserved PBSC. However, the quality control showed
that cell dose, purity, and potency were optimal. Time from
collection to cryopreservation was 4 h and the patient
Table 3 Univariate analysis of
neutrophil/platelet engraftment,
full donor chimerism, acute
GVHD, preemptive therapy on
cytomegalovirus disease, PFS,
and OS according to UD HSC.
Variable Cells P value
Fresh (N= 32) Cryopreserved (N= 32)
Neutrophils
Days to recovery, median (95% CI) 17 (14–24) 17.5 (16–21) 0.767
Rate of recovery at 21 days (95% CI) 72 (51–84) 75 (54–86) 0.850
Platelets
Days to recovery, median (95% CI) 19 (17–35.5) 25.5 (19–31) 0.192
Rate of recovery at 30 days (95% CI) 69 (48–81) 69 (47–81) 0.620
Rate of recovery at 100 days (95% CI) 94 (76–98) 97 (76–96) 0.620
Full donor chimerism
Days to achievement, median (95% CI) 31.5 (27–56.5) 35 (26–48.2) 0.872
Rate of achievement at 30 days (95% CI) 44 (24–59) 25 (8–39) 0.990
Rate of achievement at 100 days (95% CI) 75 (54–86) 84 (65–93) 0.990
Rate of acute GVHD at 100 days (95% CI) 31 (13–46) 41 (21–55) 0.380
Rate of preemptive CMV at 100 days (95% CI) 38 (18–52) 38 (18–52) 1.000
Rate of PFS at 100 days (95% CI) 81 (69–96) 88 (77–100) 0.500
OS at 100 days (95% CI) 81 (69–96) 90 (85–100) 0.300
CI confidence interval, GVHD graft-versus-host disease, CMV cytomegalovirus, PFS progression-relapse-
free survival, OS overall survival.
Table 2 Quality parameters of cryopreserved cells.
Quality test Median (IQR)
CD45+/7-AAD (%) 66.8 (52.8–74.6)
CD34+/7-AAD (%) 81.8 (66.0–94.35)
CD3+/7-AAD (%) 48.4 (33.7–64.8)
CFU-GM/kg × 105 9.0 (5.8–13.8)
Total CD34+ recovery (%) 96.2 (80.8–100)
Viable CD34+ recovery (%) 75.8 (60.5–88.4)
TNC recovery (%) 100 (99.2–100)
7-AAD 7-aminoactinomicine D, CFU-GM granulocyte/macrophage
colony-forming units, TNC, total nucleated cell.
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received RIC conditioning. Risk factors for GF other than
cryopreservation condition have been described [19]. Both
cohorts were comparable regarding acute GVHD, pre-
emptive therapy on CMV disease, PFS, and OS at 100 days.
The impact on clinical outcomes of using cryopreserved
grafts for HSCT procedures is controversial. Our findings
contrast with some studies using frozen PBSC, which con-
cluded that cryopreservation and subsequent transportation of
PBSC may impair their engraftment in allogeneic HSCT [10].
However, other studies are in line with ours [5, 9, 11]. Inter-
estingly, one study showed that the outcomes of patients who
underwent HSCT with cryopreserved or fresh PBSC were
similar in terms of neutrophil and platelet recovery, recurrence,
PFS, and OS, although the study focused on MRD HSCT [9].
Our results are also in agreement with those of a recent report
stating that cryopreservation of either MRD or UD allografts
does not delay hematopoietic recovery, increase the risk of
GVHD and PFS, or decrease OS after HSCT using GVHD
prophylaxis with PTCy [5]. Furthermore, our finding that
cryopreservation was associated with no impact on survival
had already been reported in patients who underwent HSCT
with UD HSC [11].
Although cryopreservation has undoubted advantages such
as securing graft integrity before the start of conditioning, our
study has also elicited some warnings. Six cryopreserved grafts
were donated, transported, and cryopreserved, but not finally
used, which means that 13% of donations remained stored by
the end of the study. Interestingly, a study recently carried out
by DKMS stem cell donor registry concluded that 5–10% of
cryopreserved products will not be eventually transfused [20].
The requirement of quarantine for the donations received from
countries where SARS-CoV-2 tests were not mandatory could
has increased the odds of relapse or progress among recipients,
which in fact happened in three cases, who thus lost their status
as HSCT candidates [12]. A corrective policy could be sche-
duling transplantation and collection very closely in order to
proceed with patient conditioning within a few days of UD
HSC cryopreservation, time enough for performing mandatory
quality controls. Furthermore, one product had to be discarded
due to an HLA-typing error in the first HLA test. The HLA
confirmatory result was obtained before the patient started
conditioning, but, unfortunately, after donor collection. This
kind of inconvenience may appear when work is performed
under unbearable pressure, in conditions such as those created
by COVID-19. This argument prompted us to adopt changes to
ensure rigorous quality assurance with risk assessment when
contingency plans are activated and cryopreservation is
recommended for all products.
Finally, unintended transportation issues occasionally led to
cryopreservation of grafts at origin, which resulted in last-
minute decisions. One undesired consequence was that one
external cryopreserved bag caused an allergic reaction by
DMSO due to manual transfusion at an inappropriate rate.
There were also packaging issues that might have compro-
mised the safety of HSC. To prevent these problems, the
coordination among collection centers, cell processing centers,
and TCs must improve, and logistical issues concerning ship-
ment and delivery must be anticipated. Moreover, we consider
that the development of international guidelines by reference
professional societies addressing the logistics of cryopreserva-
tion and transportation is urgently needed for adaption and























































Fig. 1 Cumulative incidence of hematological recovery and full
donor chimerism according to UD HSC (cryopreserved versus
fresh). The cumulative incidences of A neutrophil recovery, B platelet
recovery, and C full donor chimerism are shown for the groups of
patients who underwent UD HSCT with either cryopreserved (solid
line) or fresh PBSC (dashed line).
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Our study has limitations: sample size of the cohorts was
limited by the short duration of the recruitment period and
the follow-up period was also necessarily short. Grafts
subjected to major and minor manipulation, as well as BM
grafts, were excluded from the clinical outcomes analyses.
Therefore, long-term effects of cryopreservation as well as
the influence of manipulation or using BM as graft source
must be addressed in future studies.
In summary, to the best of our knowledge, this is the first
study to assess the impact of cryopreservation on UD trans-
plantation outcomes during the COVID-19 pandemic. Since no
statistical differences were found regarding engraftment,
GVHD, preemptive CMV therapy, PFS, and OS, we consider
that cryopreservation was a safe decision to maintain the UD
HSCT program in TCs. However, further studies are needed.
Importantly, wasting donations raises ethical issues, and
logistic incidents that could affect product quality or timely
delivery must be avoided. For this purpose, improvements in
disaster plans led by international guidelines and harmonization
in cryopreservation requirements are urgently needed in these
complex scenarios. More efforts are required to ensure that all
cryopreserved UD HSC are eventually transfused.
Acknowledgements We want to thank Jesus Maroto, Silvia Tuset, and
Mar Sanchez for their administrative support, and Ramón Montes for
his writing support. We also want to acknowledge BST Cell Therapy
Service technical team (Sonia Maroto, Maria Ruz, Yolanda Chacon,
Sergio Arteaga, Marina Hortola, and Camila Cardona) and cellular
laboratory (Javier Algar, Begoña Amill, Margarita Blanco, Ruth For-
ner, Daniel Navarro, Aroa Perez, and Isabel Tarrago) for their effort,
and external cell processing laboratories (Adoración Hernandez from
Blood and Tissue Bank of Granada, Raquel de Paz from Hospital
Universitario La Paz, Luis Larrea from Blood and Tissue Bank of
Valencia, and Olga Lopez from Hospital Universitario de Salamanca)
and external TC (Jaime Sanz from Hospital Universitari La Fe de
Valencia). We also thank donors, patients, couriers, Spanish and other
registries, and everyone who contributed to make UD HSCT possible
in these difficult times. Statistical analysis has been carried out in the
Statistics and Bioinformatics unit (UEB) Vall d’hebron Hospital
Researh Institue (VHIR).
Compliance with ethical standards
Conflict of interest The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to
jurisdictional claims in published maps and institutional affiliations.
References
1. Frey NV, Lazarus HM, Goldstein SC. Has allogeneic stem cell
cryopreservation been given the “cold shoulder”? An analysis of
the pros and cons of using frozen versus fresh stem cell products
in allogeneic stem cell transplantation. Bone Marrow Transpl.
2006;38:399–405.
2. Szer J, Weisdorf D, Querol S, Foeken L, Madrigal A. The impact
of COVID-19 on the provision of donor hematopoietic stem cell
products worldwide: collateral damage. Bone Marrow Transpl.
2020;23:1–2.
3. Recommendations of the European Society for Blood and Marrow
Transplantation (EBMT) regarding the situation generated by the
COVID-19 pandemic. 2020. https://www.ebmt.org/sites/default/files/












































0 25 50 10075
Days


























Fig. 2 Cumulative incidence of acute GVHD and preemptive CMV
treatment disease, PFS, and OS according to UD HSC (cryopre-
served versus fresh). The cumulative incidences of A acute graft-
versus-host disease (GVHD), B preemptive therapy on CMV disease,
C progression-relapse-free survival, and D overall survival are shown
for the groups of patients who underwent UD HSCT with either
cryopreserved (solid line) or fresh grafts (dashed line).
Cryopreservation of unrelated donor hematopoietic stem cells: the right answer for transplantations. . .
2020-03/EBMT%20COVID-19%20guidelines%20v.4.3%20%
282020-03-23%29.pdf.
4. Recommendations of the World Marrow Donor Association
(WMDA) regarding donor medical suitability in the situation gener-
ated by the COVID-19 pandemic 2021. https://share.wmda.info/pa
ges/viewpage.action?pageId=344866320.
5. Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra
S, et al. Graft cryopreservation does not impact overall survival
after allogeneic hematopoietic cell transplantation using post-
transplantation cyclophosphamide for graft-versus-host disease
prophylaxis. Biol Blood Marrow Transpl. 2020;26:1312–7.
6. Eckardt JR, Roodman GD, Boldt DH, Clark GM, Alvarez R, Page
C, et al. Comparison of engraftment and acute GVHD in patients
undergoing cryopreserved or fresh allogeneic BMT. Bone Marrow
Transpl. 1993;11:125–31.
7. Stockschläder M, Hassan HT, Krog C, Krüger W, Löliger C,
Horstman M, et al. Long-term follow-up of leukaemia patients
after related cryopreserved allogeneic bone marrow transplanta-
tion. Br J Haematol. 1997;96:382–6.
8. Shinkoda Y, Ijichi O, Tanabe T, Ishikawa S, Kamitamari A,
Nishikawa T, et al. Identical reconstitution after bone marrow
transplantation in twins who received fresh and cryopreserved
grafts harvested at the same time from their older brother. Clin
Transpl. 2004;18:743–7.
9. Kim DH, Jamal N, Saragosa R, Loach D, Wright J, Gupta V, et al.
Similar outcomes of cryopreserved allogeneic peripheral stem cell
transplants (PBSCT) compared to fresh allografts. Biol Blood
Marrow Transpl. 2007;13:1233–43.
10. Lioznov M, Dellbrugger C, Sputtek A, Fehse B, Kroger N, Zander
AR. Transportation and cryopreservation may impair haemato-
poietic stem cell function and engraftment of allogeneic PBSCs,
but not BM. Bone Marrow Transpl. 2008;42:121–8.
11. Medd P, Nagra S, Hollyman D, Craddock C, Malladi R. Cryopre-
servation of allogeneic PBSC from related and unrelated donors is
associated with delayed platelet engraftment but has no impact on
survival. Bone Marrow Transpl. 2013;48:243–8.
12. Update of October 5, 2020, of the guidelines of the Spanish
National Transplant Organization (Spain Ministry of Health,
Consumer Affairs and Social Welfare) about the impact of SARS-
CoV-2 and COVID-19 on donation and transplantation, reference
BV-ES-20200122-11. http://www.ont.es/infesp/Paginas/COVID-
19.aspx.
13. Lanza F, Saccardi R, Seghatchian J. New horizons on stem cell
cryopreservation through the artificial eyes of CD34 using modern
flow cytometry tools. Transfus Apher Sci. 2020;59:
102785.
14. Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P,
Hows J, et al. 1994 consensus conference on acute GVHD
grading. Bone Marrow Transpl. 1995;15:825–8.
15. Jagasia MH, Greinix HT, Arora M, Williams KM, Wolff D,
Cowen EW, et al. National Institutes of Health consensus
development project on criteria for clinical trials in chronic
graft-versus-host disease: I. The 2014 Diagnosis and Staging
Working Group report. Biol Blood Marrow Transpl.
2015;21:389–401. e1.
16. Shaw BE, Chapman J, Fechter M, Foeken L, Greinix H, Hwang
W, et al. Towards a global system of vigilance and surveillance in
unrelated donors of haematopoietic progenitor cells for trans-
plantation. Bone Marrow Transpl. 2013;48:1506–9.
17. Mattsson J, Ringdén O, Storb R. Graft failure after allogeneic
hematopoietic cell transplantation. Biol Blood Marrow Transpl.
2008;14:165–70.
18. Torlen J, Ringden O, Le Rademacher J, Batiwalla M, Chen J,
Erkers T, et al. Low CD34 dose is associated with poor survival
after reduced-intensity conditioning allogeneic transplantation for
acute myeloid leukemia and myelodysplastic syndrome. Biol
Blood Marrow Transpl. 2014;20:1418–25.
19. Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell
BJ, et al. Primary graft failure after myeloablative allogeneic
hematopoietic cell transplantation for hematologic malignancies.
Leukemia. 2015;29:1754–62.
20. Schmidt AH, Buk D, Platz A, van den Brink MRM. Cryopre-
servation for all is no option in unrelated stem cell transplantation.
Comment on Dholaria B, et al. securing the graft during pan-
demic: are we ready for cryopreservation for all? Biol Blood
Marrow Transpl. 2020;26:e145–6.
J. Fernandez-Sojo et al.
